Geode Capital Management LLC Boosts Stock Position in Singular Genomics Systems, Inc. (NASDAQ:OMIC)

Geode Capital Management LLC lifted its position in Singular Genomics Systems, Inc. (NASDAQ:OMIC) by 7.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,962 shares of the company’s stock after purchasing an additional 1,193 shares during the quarter. Geode Capital Management LLC’s holdings in Singular Genomics Systems were worth $282,000 at the end of the most recent quarter.

Singular Genomics Systems Trading Up 0.9 %

NASDAQ OMIC opened at $19.80 on Tuesday. Singular Genomics Systems, Inc. has a 1-year low of $5.34 and a 1-year high of $23.41. The company has a current ratio of 7.37, a quick ratio of 6.67 and a debt-to-equity ratio of 0.04. The stock has a 50-day moving average of $20.76 and a 200-day moving average of $14.07. The firm has a market cap of $49.74 million, a PE ratio of -0.56 and a beta of 1.82.

Singular Genomics Systems (NASDAQ:OMIC) last released its earnings results on Tuesday, November 12th. The company reported ($6.72) earnings per share for the quarter, beating analysts’ consensus estimates of ($8.05) by $1.33. Singular Genomics Systems had a negative return on equity of 57.87% and a negative net margin of 3,237.89%. The company had revenue of $0.41 million during the quarter, compared to analyst estimates of $0.74 million.

About Singular Genomics Systems

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.